Navigation Links
InteKrin Therapeutics' Co-Founder Receives Appointment as Professor of Medicine at Harvard Medical School
Date:2/8/2010

LOS ALTOS, Calif., Feb. 8 /PRNewswire/ -- InteKrin Therapeutics Inc announced today that the Company's co-founder and Scientific Advisory Board Chairman, Christos Mantzoros, M.D., DSc., FACP, FACE, has been appointed Professor of Medicine at Harvard Medical School and Professor in Environmental Health at the Harvard School of Public Health.

Dr. Mantzoros is a member of Harvard's Division of Endocrinology, Diabetes, and Metabolism, and is an acknowledged expert in the fields of insulin resistance, body weight regulation, adipokine biology, and energy homeostasis. He has published more than 200 original papers and more than 100 reviews and chapters which have received more than 12,000 citations. He has received several national and international awards and has also been elected a member of The American Society for Clinical Investigation (ASCI).

Dr. Mantzoros, who trained at Harvard, serves as Founding Director of the Human Nutrition Research Unit and as the Clinical Research Overseer at Beth Israel Deaconess Medical Center and the Joslin Diabetes Center. In conjunction with his new appointment, he will also be assuming responsibilities as Chief of Endocrinology and Diabetes at the Greater Boston VA Healthcare System, a system of three hospitals and six outpatient clinics in the greater Boston area which are affiliated with Harvard Medical School.

Dennis M. Lanfear, President and Chief Executive Officer, and Dr. Mantzoros founded InteKrin Therapeutics Inc in 2005. Dr. Mantzoros remains an integral part of InteKrin Therapeutics' management team and regularly advises on scientific matters.

About InteKrin (www.InteKrin.com):

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders.

SOURCE InteKrin Therapeutics Inc


'/>"/>
SOURCE InteKrin Therapeutics Inc
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InteKrin Therapeutics Presents Positive Long Term INT131 Preclinical Cardiovascular Safety Data at the 45th Annual European Association for the Study of Diabetes Meeting
2. InteKrin Therapeutics to Present at the 2009 American Diabetes Association Annual Meeting
3. InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
4. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
5. BioMarin to Acquire LEAD Therapeutics
6. Medical Research Council Technologys Centre for Therapeutics Discovery Opens its First Call For Targets in an Effort to Develop Drugs in Areas of Serious Unmet Need
7. Vantia Therapeutics Lead Candidate VA106483 Enters Phase IIb Trial for Nocturia
8. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
9. Pepscan Therapeutics Strengthens Management Team
10. PTC Therapeutics Announces Additional Study of Ataluren in Patients with Advanced Nonsense Mutation Duchenne/Becker Muscular Dystrophy
11. NASDAQ Trading for Oxygen Biotherapeutics, Inc. Shares to Begin January 15, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... MOUNTAIN VIEW, Calif. , June 23, 2016 ... 9:00 a.m. CST on Thursday, July 7, 2016 , , ... kayla.belcher@frost.com ) , , , , EXPERT PANELISTS:  ... Sciences, Nitin Naik; Senior Industry Analyst, Christi Bird; Senior Industry Analyst, ... The global pharmaceutical industry is witnessing ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ... , "Film editors can give their videos a whole new perspective by using the ... CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
Breaking Medicine News(10 mins):